BDBM242758 US10030025, Compound 23::US10836768, Cpd no 23::US11731974, Compound 23::US20240199618, Compound 23::US9422299, 23::US9987274, Compound 23

SMILES CCC1N(CCn2c1nnc2-c1nc(C)ns1)C(=O)c1ccc(F)cc1

InChI Key InChIKey=OZKSTTVUQRWBIO-UHFFFAOYSA-N

Data  8 KI  3 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 242758   

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataIC50: 220nMAssay Description:Chinese Hamster Ovary recombinant cells expressing the human NK-3 receptor and a construct that encodes the photoprotein apoaequorin were used for th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2017
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataIC50: 220nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataIC50: 220nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataKi:  150nMpH: 7.4Assay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2017
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataKi:  150nMpH: 7.4Assay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataKi:  150nMAssay Description:Human NK-3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2020
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataKi:  150nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataKi:  150nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist3 H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2023
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataKi:  150nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist3 H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2023
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataKi:  150nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/24/2024
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM242758(US9422299, 23 | US10030025, Compound 23 | US998727...)
Affinity DataKi:  150nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/24/2024
Entry Details
Go to US Patent